Lilly’s Zepbound Cut Risk of Diabetes by 94% in Obese People
Bloomberg Businessweek
00:00
Intro
This chapter examines a three-year study revealing Eli Lilly's ZEP Bound significantly reduces diabetes risk by 94% in patients. It underscores the importance of long-term data on GLP-1 drugs, showcasing their enduring benefits in weight management and chronic disease prevention.
Transcript
Play full episode
